Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOS NASDAQ:ENLV NASDAQ:GALT NASDAQ:MIRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.40+1.1%$2.49$1.05▼$3.60$173.71M0.34618,556 shs48,278 shsENLVEnlivex Therapeutics$0.69+2.8%$0.80$0.66▼$2.10$163.32M1.47491,745 shs74,453 shsGALTGalectin Therapeutics$2.72+1.9%$2.38$1.38▼$7.13$179.14M0.47335,233 shs30,335 shsMIRAMIRA Pharmaceuticals$0.98+4.0%$1.02$0.90▼$2.45$41.10M1.43147,264 shs13,237 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals0.00%+10.23%+3.95%-29.04%+121.50%ENLVEnlivex Therapeutics0.00%-5.62%-7.01%-37.95%-25.96%GALTGalectin Therapeutics0.00%+14.59%+23.04%-16.04%+94.89%MIRAMIRA Pharmaceuticals0.00%-6.00%-2.39%-22.31%-22.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.40+1.1%$2.49$1.05▼$3.60$173.71M0.34618,556 shs48,278 shsENLVEnlivex Therapeutics$0.69+2.8%$0.80$0.66▼$2.10$163.32M1.47491,745 shs74,453 shsGALTGalectin Therapeutics$2.72+1.9%$2.38$1.38▼$7.13$179.14M0.47335,233 shs30,335 shsMIRAMIRA Pharmaceuticals$0.98+4.0%$1.02$0.90▼$2.45$41.10M1.43147,264 shs13,237 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals0.00%+10.23%+3.95%-29.04%+121.50%ENLVEnlivex Therapeutics0.00%-5.62%-7.01%-37.95%-25.96%GALTGalectin Therapeutics0.00%+14.59%+23.04%-16.04%+94.89%MIRAMIRA Pharmaceuticals0.00%-6.00%-2.39%-22.31%-22.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 2.50Moderate Buy$6.67179.52% UpsideENLVEnlivex Therapeutics 2.00Hold$16.502,287.84% UpsideGALTGalectin Therapeutics 2.00Hold$11.00311.99% UpsideMIRAMIRA Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest MIRA, ENLV, GALT, and ABOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026ABOSAcumen Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026ENLVEnlivex Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $20.003/27/2026MIRAMIRA Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/26/2026ABOSAcumen Pharmaceuticals BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.003/16/2026ABOSAcumen Pharmaceuticals BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $8.00(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$1.16 per shareN/AENLVEnlivex TherapeuticsN/AN/AN/AN/A$8.15 per shareN/AGALTGalectin TherapeuticsN/AN/AN/AN/A($1.99) per shareN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.25 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$121.33M-$1.86N/AN/AN/AN/A-123.07%-79.41%8/11/2026 (Estimated)ENLVEnlivex Therapeutics$1.24B-$0.55N/AN/AN/AN/A248.08%206.39%8/24/2026 (Estimated)GALTGalectin Therapeutics-$30.84M-$0.41N/AN/AN/AN/AN/A-164.69%8/13/2026 (Estimated)MIRAMIRA Pharmaceuticals-$10.44M-$1.30N/AN/AN/AN/A-140.82%-135.01%9/2/2026 (Estimated)Latest MIRA, ENLV, GALT, and ABOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026GALTGalectin Therapeutics-$0.06-$0.08-$0.02-$0.08N/AN/A5/14/2026Q1 2026MIRAMIRA PharmaceuticalsN/A-$0.03N/A-$0.03N/AN/A5/12/2026Q1 2026ABOSAcumen Pharmaceuticals-$0.4028-$0.33+$0.0728-$0.33N/AN/A3/31/2026Q4 2025GALTGalectin Therapeutics-$0.10-$0.08+$0.02-$0.08$36.32 millionN/A3/26/2026Q4 2025ABOSAcumen Pharmaceuticals-$0.50-$0.41+$0.09-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.194.554.55ENLVEnlivex TherapeuticsN/A193.24193.24GALTGalectin TherapeuticsN/A2.152.15MIRAMIRA PharmaceuticalsN/A82.1582.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%ENLVEnlivex Therapeutics1.02%GALTGalectin Therapeutics11.68%MIRAMIRA Pharmaceuticals35.16%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals10.20%ENLVEnlivex Therapeutics12.28%GALTGalectin Therapeutics52.60%MIRAMIRA Pharmaceuticals6.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2072.23 million64.86 millionOptionableENLVEnlivex Therapeutics70237.38 million208.23 millionOptionableGALTGalectin Therapeutics965.86 million31.22 millionOptionableMIRAMIRA Pharmaceuticals242.02 million39.23 millionNot OptionableMIRA, ENLV, GALT, and ABOS HeadlinesRecent News About These CompaniesMIRA Pharmaceuticals Appoints New Fractional Chief Financial OfficerJune 8, 2026 | tipranks.comAnalyzing Curis (NASDAQ:CRIS) & MIRA Pharmaceuticals (NASDAQ:MIRA)June 5, 2026 | americanbankingnews.comMIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1June 4, 2026 | accessnewswire.comAMIRA Expands Global Ketamir-2 License for Clinical DevelopmentMay 27, 2026 | tipranks.comMIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPNMay 27, 2026 | accessnewswire.comAMira Pharmaceuticals stock gains on Phase 1 trial resultsMay 14, 2026 | investing.comMIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2May 14, 2026 | accessnewswire.comAMIRA highlights SKNY-1 preclinical data in new publicationMay 13, 2026 | tipranks.comMIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug CandidateMay 13, 2026 | accessnewswire.comAVisionstate Reports 27% Q2 Revenue Growth as MIRA Platform Gains TractionMay 6, 2026 | newsfilecorp.comNWhat's going on with MIRA Pharma stock Tuesday?March 24, 2026 | msn.comMIRA Pharmaceuticals Highlights Encouraging Safety Data for Mira-55March 23, 2026 | tipranks.comMIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical StudiesMarch 23, 2026 | accessnewswire.comAMIRA Pharmaceuticals completes dosing in Ketamir-2 Phase I trialMarch 5, 2026 | yahoo.comMIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2March 4, 2026 | accessnewswire.comAMIRA Completes Phase 1 Trial of Ketamir-2 TherapyMarch 3, 2026 | tipranks.comWhy MIRA Pharmaceuticals, Inc.’s (MIRA) Stock Is Down 13.39%March 3, 2026 | aaii.comAVisionstate Repositions Under MIRA Compliance Platform and Reports Subscription GrowthFebruary 19, 2026 | newsfilecorp.comNMIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a StudyFebruary 3, 2026 | accessnewswire.comAMIRA Pharmaceuticals Advances Ketamir-2 Phase 1 to Final CohortFebruary 2, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMIRA, ENLV, GALT, and ABOS Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$2.40 +0.03 (+1.05%) As of 10:10 AM Eastern This is a fair market value price provided by Massive. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Enlivex Therapeutics NASDAQ:ENLV$0.69 +0.02 (+2.82%) As of 10:10 AM Eastern This is a fair market value price provided by Massive. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Galectin Therapeutics NASDAQ:GALT$2.72 +0.05 (+1.87%) As of 09:44 AM EasternGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.MIRA Pharmaceuticals NASDAQ:MIRA$0.98 +0.04 (+4.04%) As of 10:09 AM Eastern This is a fair market value price provided by Massive. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Meta to Follow Alphabet's Footsteps? What an Equity Raise Could Mean Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
